NASDAQ:INMB

Inmune Stock Insider Trading

Healthcare > Biotechnology

Buy INMB

*Your capital is at risk

$1.32

-0.1000 (-7.04%)

At Close: Jun 03, 2026

Inmune Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -68.98. In total, the insiders bought 5.8M and sold 4M INMB shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-68.98
● Buy	5.8M shares
● Sell	4M shares
51% Buy Activity Moderate Positive Correlation
Sell Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -68.98. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Dec 01, 2025 Buy	Option (right to buy) A-Award	Allen Marcia Director	Director	150 000 Value: $222.0K
Dec 01, 2025 Buy	Option (right to buy) A-Award	Ganjei James Kelly Director	Director	150 000 Value: $222.0K
Dec 01, 2025 Buy	Option (right to buy) A-Award	Juda Scott Director	Director	150 000 Value: $222.0K
Dec 01, 2025 Buy	Option (right to buy) A-Award	Schroeder Timothy J Director	Director	150 000 Value: $222.0K
Dec 01, 2025 Buy	Option (right to buy) A-Award	Ellspermann Cory Randall CFO	C-Suite Officer	300 000 Value: $444.0K
Dec 01, 2025 Buy	Option (right to buy) A-Award	Moss David J Chief Executive Officer	CEO / President	750 000 Value: $1.11M
Dec 01, 2025 Buy	Option (right to buy) A-Award	Lowdell Mark William Chief Scientific Officer	Officer	600 000 Value: $888.0K
Nov 18, 2025 Sell	Stock Option (right to buy) D-Return	Allen Marcia Director	Director	108 000 Value: $422.3K
Nov 18, 2025 Sell	Stock Option (right to buy) D-Return	Allen Marcia Director	Director	12 500 Value: $124.0K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Allen Marcia Director	Director	12 500 Value: $18.8K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Allen Marcia Director	Director	15 975 Value: $24.0K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Allen Marcia Director	Director	19 025 Value: $28.5K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Allen Marcia Director	Director	32 500 Value: $48.8K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Allen Marcia Director	Director	35 000 Value: $52.5K
Nov 18, 2025 Sell	Stock Option (right to buy) D-Return	Ellspermann Cory Randall Interim CFO	C-Suite Officer	70 000 Value: $353.5K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Ellspermann Cory Randall Interim CFO	C-Suite Officer	30 000 Value: $45.0K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Ellspermann Cory Randall Interim CFO	C-Suite Officer	40 000 Value: $60.0K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Ellspermann Cory Randall Interim CFO	C-Suite Officer	70 000 Value: $105.0K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Ellspermann Cory Randall Interim CFO	C-Suite Officer	75 000 Value: $112.5K
Nov 18, 2025 Sell	Stock Option (right to buy) D-Return	Ganjei James Kelly Director	Director	19 025 Value: $332.7K
Nov 18, 2025 Sell	Stock Option (right to buy) D-Return	Ganjei James Kelly Director	Director	15 975 Value: $396.5K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Ganjei James Kelly Director	Director	35 000 Value: $52.5K
Nov 18, 2025 Buy	Stock Option (right to buy) A-Award	Ganjei James Kelly Director	Director	108 000 Value: $162.0K
Nov 18, 2025 Sell	Stock Option (right to buy) D-Return	Juda Scott Director	Director	35 000 Value: $340.9K
Nov 18, 2025 Sell	Stock Option (right to buy) D-Return	Juda Scott Director	Director	35 000 Value: $277.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT INMUNE BIO INC.

INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic synd...

Read Full Profile Here